Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 11/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.35 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.35 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26644299 | 1.00 | WEE1 (0.36) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL26644291 | 1.00 | WEE1 (0.36) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL30656088 | 0.90 | WEE1 (0.35) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL26644328 | 0.90 | WEE1 (0.35) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL26644330 | 0.90 | WEE1 (0.35) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL26644436 | 0.81 | WEE1 (0.36) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL26644550 | 0.77 | WEE1 (0.62) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL26644546 | 0.77 | WEE1 (0.62) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL25100722 | 0.76 | WEE1 (0.39) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL25100720 | 0.76 | WEE1 (0.39) | WEE1EGFRCYP3A4PLK1MAP3K19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023217201-A2 | NOVEL PYRIMIDO-HETEROCYCLIC NOVEL COMPOUND SERVING AS WEE1 INHIBITOR AND APPLICATION THEREOF | 杭州德睿智药科技有限公司 | 2023-11-16 | — | — | WO | disclosed |